Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by Atria Investments Inc

Atria Investments Inc increased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 6.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,365 shares of the biopharmaceutical company’s stock after purchasing an additional 737 shares during the quarter. Atria Investments Inc’s holdings in Agios Pharmaceuticals were worth $373,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Street Corp raised its holdings in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares during the last quarter. Erste Asset Management GmbH acquired a new position in Agios Pharmaceuticals during the third quarter worth $97,199,000. Geode Capital Management LLC raised its holdings in Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after purchasing an additional 6,101 shares during the last quarter. Frazier Life Sciences Management L.P. raised its holdings in Agios Pharmaceuticals by 19.7% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock worth $46,392,000 after purchasing an additional 172,180 shares during the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Agios Pharmaceuticals by 12.3% in the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company’s stock worth $31,567,000 after acquiring an additional 105,333 shares during the last quarter.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $30.93 on Monday. The firm has a market capitalization of $1.77 billion, a PE ratio of 2.73 and a beta of 0.90. The business has a 50-day moving average of $33.70 and a two-hundred day moving average of $41.76. Agios Pharmaceuticals, Inc. has a 12 month low of $27.14 and a 12 month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AGIO. Scotiabank boosted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. HC Wainwright began coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Finally, StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $56.57.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.